Trials / Terminated
TerminatedNCT01910844
Phase II Pilot Study Assessing Efficacy of a Cisplatin - Métronomic Cyclophosphamide Treatment in Patients With Stade IV Triple Negative Breast Cancer Secondary Resistant to Anthracyclines and Taxanes
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- Centre Jean Perrin · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Study assessing efficacy of a Cisplatine- Métronomic cyclophosphamide treatment in Patients with Metastatic Triple Negative breast Cancer Secondary Resistant to Anthracyclines and Taxanes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cisplatin | 25 mg/m² I.V. from day 1 to day 3 - total dose = 75 mg/m² every 3 weeks |
| DRUG | Cyclophosphamide | Metronomic cyclophosphamide per os 150 mg from day 1 to day 14 - total dose 2100 mg every 3 weeks |
Timeline
- Start date
- 2013-07-01
- Primary completion
- 2016-09-01
- Completion
- 2016-09-01
- First posted
- 2013-07-30
- Last updated
- 2016-10-11
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT01910844. Inclusion in this directory is not an endorsement.